Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Issue of Shares

October 3, 2023
RNS Number : 5660O Renalytix PLC 03 October 2023     Renalytix plc ("Renalytix" or the "Company")   Issue of Shares   LONDON and SALT LAKE CITY , October 3, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 75,328 new

Medicare prices kidneyintelX.dkd at $950

October 3, 2023
RNS Number : 4486O Renalytix PLC 03 October 2023     THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO. Renalytix plc ("Renalytix" or the "Company")  

Renalytix Reports Full Year Fiscal 2023 Results

September 28, 2023
RNS Number : 9254N Renalytix PLC 28 September 2023   Renalytix plc ("Renalytix" or the "Company")   Renalytix Reports Full Year Fiscal 2023 Results   LONDON and SALT LAKE CITY , September 28, 2023   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics

Notice of Results

September 25, 2023
RNS Number : 4406N Renalytix PLC 25 September 2023     Renalytix plc ("Renalytix" or the "Company")     Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28   LONDON and SALT LAKE CITY , September 25, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX)

Payer coverage expansion of KidneyIntelX

September 22, 2023
RNS Number : 2884N Renalytix PLC 22 September 2023     THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO.

Appointment of Chief Business Officer

September 7, 2023
RNS Number : 6395L Renalytix PLC 07 September 2023     Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort   LONDON and SALT LAKE CITY -   September 07, 2023 - Renalytix plc

Business Update

August 21, 2023
RNS Number : 8461J Renalytix PLC 21 August 2023     THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING FOR THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO.

RSU vesting for employees

August 3, 2023
RNS Number : 2096I Renalytix PLC 03 August 2023     Renalytix plc ("Renalytix" or the "Company")   RSU vesting for employees   LONDON and SALT LAKE CITY , August 3, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that 92,770 Restricted Stock Units ("RSUs") previously

Formation of Clinical Advisory Board

August 3, 2023
RNS Number : 1362I Renalytix PLC 03 August 2023     Renalytix plc ("Renalytix" or the "Company")   Formation of Clinical Advisory Board   Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd  World leading, multi-disciplinary experts advise on adoption of FDA

Vector Pharma Middle East Distribution Agreement

July 21, 2023
RNS Number : 7254G Renalytix PLC 21 July 2023     Renalytix plc ("Renalytix" or the "Company")   Middle East Distribution Agreement with Vector Pharma   Commercial availability of kidneyintelX.dkd™ expanded to an estimated 4 million DKD Patients in the Middle East   Distribution agreement opens
Displaying 81 - 90 of 347